Predictors for weight loss after Roux-en-Y gastric bypass: the trend and associated factors for weight loss

• Published in: BMC surgery Vol. 22; no. 1; pp. 1 - 310
• Main Authors: Eghbali, Foolad, Bahardoust, Mansour, Pazouki, Abdolreza, Barahman, Gelayol, Tizmaghz, Adnan, Hajmohammadi, Amir, Karami, Reza, Hosseini-Baharanchi, Fatemeh Sadat
• Format: Journal Article
• Language: English
• Published: London BioMed Central Ltd 11.08.2022; BioMed Central; BMC
• Subjects: Age; Bariatric surgery; Blood pressure; Body weight loss; Comorbidity; Comparative analysis; Diabetes; Diabetes mellitus; Diabetics; Gastric bypass; Gastrointestinal surgery; Hypertension; Hypothyroidism; Laparoscopy; Medical research; Medicine, Experimental; Obesity; Patients; Roux-en-Y gastric bypass; Surgery; Sutures; Type 2 diabetes; Weight control; Weight loss
• ISSN: 1471-2482; 1471-2482
• DOI: 10.1186/s12893-022-01760-3

Abstract Background Historically, Roux-en-Y gastric bypass (RYGB) has been considered the gold standard of bariatric surgery (BS). This procedure acts as a mixed restrictive and malabsorptive operation. Methods  This retrospective cohort study included 410 morbidly obese patients (BMI > 40 kg/m 2 or BMI > 35 kg/m 2  along with at least one major comorbidity) who underwent primary laparoscopic RYGB surgery from 2009 to 2015 by a single surgery team. The patients were 18 years and older with at least 12 months of follow-up. Total weight loss (%TWL) and comorbidity resolution were compared in short-term (12 months) and mid-term (12–60 months) follow-ups. The primary and secondary outcomes were evaluating the effect of Roux-en-Y on weight loss and control of comorbidities, respectively. Results  The mean ± SD age, weight, and BMI at surgery were 40.1 ± 10.58 years, 123.32 ± 19.88 kg, and 45.78 ± 5.54 kg/m 2 , respectively, and 329 (80%) were female, and 62 (15%) had T2DM. %TWL was significantly higher in T2DM patients 9 months postoperatively and after that. Patients with lower BMI (< 50 kg/m 2 ) at surgery and non-diabetic patients had a significantly lower %TWL over a short- and long-term follow-up (P < 0.001). Conclusions BS remains the most efficacious and durable weight loss treatment. However, a proportion of patients will experience insufficient weight loss following BS.